Pulmonary toxicities of biologics: A review

Anti-Cancer Drugs

Volumn 21, Issue 2, 2010, Pages 131-139

  Peerzada, Maajid Mumtaz ^a   Spiro, Timothy P ^a   Daw, Hamed A ^a  

^a FAIRVIEW HOSPITAL   (United States)

Author keywords

Biologics; Interstitial lung disease; Pulmonary toxicities

Indexed keywords

ALEMTUZUMAB; BETAMETHASONE; BEVACIZUMAB; BLEOMYCIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PENTAMIDINE; PIPERACILLIN PLUS TAZOBACTAM; PREDNISOLONE; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TRASTUZUMAB; UNINDEXED DRUG; VANCOMYCIN; VINCRISTINE; VINDESINE; VORICONAZOLE;

ADULT RESPIRATORY DISTRESS SYNDROME; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; B CELL LYMPHOMA; BIOLOGICAL THERAPY; BREAST CANCER; BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; BRONCHOSPASM; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COLORECTAL CANCER; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; FIBROSING ALVEOLITIS; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; HEAD AND NECK CANCER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFUSION SITE REACTION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LARGE CELL LYMPHOMA; LOEFFLER PNEUMONIA; LUNG ALVEOLITIS; LUNG FIBROSIS; LUNG GRANULOMA; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; LYMPHOCYTOPENIA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; ORGANIZING PNEUMONIA; PAROTID GLAND CANCER; PRIORITY JOURNAL; RECURRENT CANCER; RESPIRATORY FAILURE; RESTRICTIVE LUNG DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TESTIS CANCER; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC AGENTS; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; NEOPLASMS;

EID: 76149131685     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328333d662     Document Type: Review

References (66)

1. Zerga M, Cerchetti L, Cicco J, Constantini P, De Riz M, Elsner B, et al. Desquamative alveolitis: an unusual complication of treatment with mabthera. Blood 1999; 94 (Suppl):271S.
2. Davis TA, White CA, Grillo-López AJ, Velásquez WS, Link B, Maloney DG, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17:1851-1857.
3. Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma 2001; 42:1329-1337.
4. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101:6-14.
5. Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003; 348:2690-2691.
6. Hainsworth JD, Litchy S, Lamb MR, Rodriguez GI, Scroggin C Jr, Greco FA. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial. Clin Lymphoma 2003; 4:36-42.
7. Swords R, Power D, Fay M, O'Donnell R, Murphy PT. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 2004; 77:103-104.
8. Jullien V, Perrin C, Peyrade F, Lemoigne F, Chichmanian RM, Blaive B. Alveolar hypoxemic interstitial pneumonia related to rituximab therapy. Rev Mal Respir 2004; 21 (2 Pt 1):407-410.
9. Leon RJ, Gonsalvo A, Salas R, Hidalgo NC. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc 2004; 79:949-953.
10. Alexandrescu DT, Dutcher JP, O'Boyle K, Albulak M, Oiseth S,Wiernik PH. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004; 45:2321-2325.
11. Hiraga J, Kondoh Y, Taniguchi H, Kinoshita T, Naoe T. A case of interstitial pneumonia induced by rituximab therapy. Int J Hematol 2005; 81:169-170.
12. Ghesquieres H. Severe interstitial pneumonitis following rituximab and bleomycin-containing combination chemotherapy. Ann Oncol 2005; 16:1399.
13. Herishanu Y, Polliack A, Leider-Trejo L, Grieff Y, Metser U, Naparstek E. Fatal interstitial pneumonitis related to rituximab-containing regimen. Clin Lymphoma Myeloma 2006; 6:407-409.
14. Mian M, Rass C, Hutarew G, Kofler B, Fiegl M, Greil R. Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature. Leuk Lymphoma 2006; 47:1683-1685.
15. Lee Y, Kyung SY, Choi SJ, Bang SM, Jeong SH, Shin DB, Lee JH. Two cases of interstitial pneumonitis caused by rituximab therapy. Korean J Intern Med 2006; 21:183-186.
16. Biehn SE, Kirk D, Rivera MP, Martinez AE, Khandani AH, Orlowski RZ. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. Hematol Oncol 2006; 24:234-237.
17. Heresi GA, Farver CF, Stoller JK. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration 2008; 76:449-453.
18. Kim KM, Kim HC, Jeon KN, Kim HG, Kang JH, Hahm JR, Lee GW. Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. Yonsei Med J 2008; 49:155-158.
19. Wu SJ, Chou WC, Ko BS, Tien HF. Severe pulmonary complications after initial treatment with rituximab for the Asian-variant of intravascular lymphoma. Haematologica 2007; 92:141-142.
20. Liu X, Hong XN, Gu YJ, Wang BY, Luo ZG, Cao J. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leuk Lymphoma 2008; 49:1778-1783.
21. Montero AJ, McCarthy JJ, Chen G, Rice L. Acute respiratory distress syndrome after rituximab infusion. Int J Hematol 2005; 82:324-326.
22. Saito B, Nakamaki T, Adachi D, Suzuki J, Tomoyasu S. Acute respiratory distress syndrome during the third infusion of rituximab in a patient with follicular lymphoma. Int J Hematol 2004; 80:164-167.
23. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007; 82:916-919.
24. Soubrier M, Jeannin G, Kemeny JL, Tournadre A, Caillot N, Caillaud D, Dubost JJ. Organizing pneumonia after rituximab therapy: two cases. Joint Bone Spine 2008; 75:362-365.
25. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456-473.
26. Schlesinger C, Koss MN. The organizing pneumonias: an update and review. Curr Opin Pulm Med 2005; 11:422-430.
27. Cordier JF. Cryptogenic organising pneumonia. Eur Respir J 2006; 28:422-446.
28. Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2001;2:378-384.
29. Van der Kolk LE, Grillo-López AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115:807-811.
30. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokinerelease syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94:2217-2224.
31. Leard LE, Cho BK, Jones KD, Hays SR, Tope WD, Golden JA, Hoopes CW. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant 2007; 26:1340-1344.
32. Kaza AK, Cope JT, Fiser SM, Long SM, Kern JA, Tribble CG, et al. Contrasting natures of lung growth after transplantation and lobectomy. J Thorac Cardiovasc Surg 2002; 123:288-294.
33. National Cancer Institute. Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer, March 14 2005. Available at http://www.nci.nih.gov/newscenter/pressreleases/ avastinlung. [Accessed 12 December 2006]
34. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-2191.
35. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550. Erratum in: N Engl J Med 2007; 356:318. (Pubitemid 44917502)
36. Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004; 38:1258-1264.
37. Zhao L, Wang K, Ferrara N, Vu TH. Vascular endothelial growth factor co-ordinates proper development of lung epithelium and vasculature. Mech Dev 2005; 122:877-886.
38. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003; 21:3542.
39. Cho YJ, Murgu SD, Colt HG. Bronchoscopy for bevacizumab-related hemoptysis. Lung Cancer 2007; 56:465-468.
40. Hsiao EI, Kirsch CM, Kagawa FT,Wehner JH, Jensen WA, Baxter RB. Utility of fiberoptic bronchoscopy before bronchial artery embolization for massive hemoptysis. AJR Am J Roentgenol 2001;177:861-867.
41. Colt HG. Laser bronchoscopy. Chest Surg Clin N Am 1996; 6:277-291.
42. Lee P, Kupeli E, Mehta AC. Therapeutic bronchoscopy in lung cancer. Laser therapy, electrocautery, brachytherapy, stents, and photodynamic therapy. Clin Chest Med 2002; 23:241-256.
43. Polanyi TG. Physics of surgery with lasers. Clin Chest Med 1985; 6:179-202.
44. Prat A, Martínez P, Serrano C, Montero MA, Andreu J, Cortés J. Acute lung injury associated with docetaxel and bevacizumab. Clin Oncol (R Coll Radiol) 2007; 19:803-805.
45. Robak T. Alemtuzumab in the treatment of chronic lymphocytic leukemia. Bio Drugs 2005; 19:9-22.
46. Qu Z, Griffiths GL,Wegener WA, Chang CH, Govindan SV, Horak ID, et al. Development of humanized antibodies as cancer therapeutics. Methods 2005; 36:84-95.
47. Creelan B, Ferber A. A fatal case of alemtuzumab-associated interstitial pneumonitis. Am J Ther 2008; 15:82-84.
48. Uppenkamp M, Engert A, Diehl V, Bunjes D, Huhn D, Brittinger G. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high-grade and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Ann Hematol 2002; 81:26-32.
49. Rieger K, Von Grünhagen U, Fietz T, Thiel E, Knauf W. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia -change of regimen needed? Leuk Lymphoma 2004; 45:345-349.
50. Sachdeva A, Matuschak GM. Diffuse alveolar hemorrhage following alemtuzumab. Chest 2008; 133:1476-1478.
51. Schwarz MI, Fontenot AP. Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis. Clin Chest Med 2004; 25:133-140.
52. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23:4265-4274.
53. Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23:2162-2171.
54. Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 2001; 61 (Suppl 2):58-66.
55. Radzikowska E, Szczepulska E, Chabowski M, Bestry I. Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer. Eur Respir J 2003; 21:552-555.
56. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684.
57. Clamon G, Herndon J, Kern J, Govindan R, Garst J, Watson D, Green M, Cancer and Leukemia Group B. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer 2005; 103:1670-1675.
58. Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Müller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 2002; 57:292-299.
59. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 2006; 17:372-379.
60. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration 2004; 71:301-326. (Pubitemid 39179164)
61. Camus PH, Foucher P, Bonniaud PH, Ask K. Drug induced infiltrative lung disease. Eur Respir J 2001;18 (Suppl 32):93s-100s.
62. Attabai K, Ishigaki M, Geiser T, Ueki I, Matthay MA, Ware LB. Keratinocyte growth factor can enhance alveolar epithelial repair by nonmitogenic mechanisms. Am J Physiol Lung Cell Mol Physiol 2002; 283:163-169.
63. Herceptin (Trastuzumab). US Food and Drug Administration, 2005. [Cited 15 November 2005]. Available from URL: http://www.fda.gov/ medwatch/safety/2005/ herceptin-Promo-PDF-Feb-2005.pdf
64. Pepels MJ, Boomars KA, van Kimmenade R, Hupperets PS. Life-threatening interstitial lung disease associated with trastuzumab: case report. Breast Cancer Res Treat 2009; 113:609-612.
65. Vahid B, Mehrotra A. Trastuzumab (Herceptin)-associated lung injury. Respirology 2006; 11:655-658.
66. Bettini AC, Tondini C, Poletti P, Caremoli ER, Guerra U, Labianca R. A case of interstitial pneumonitis associated with Guillain-Barre syndrome during administration of adjuvant trastuzumab. Tumori 2008; 94:737-741.